MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion
China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362...
Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-1738 and HRS-5817 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical Products...
MicroPort MedBot Reports Strong 2024 Growth for Toumai and SkyWalker Robots
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) revealed its 2024 financial performance, recording RMB257...
Sanofi’s mRNA Chlamydia Vaccine Gains FDA Fast Track Designation
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving fast track designation from...
Fangzhou Inc. Partners with Tencent Health to Advance AI-Driven Healthcare Solutions
Guangzhou-based smart healthcare service platform Fangzhou Inc. (HKG: 6086) has announced a strategic partnership with...
Merck, Sharp & Dohme’s Capvaxive Approved by European Commission for Pneumococcal Prevention
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the European Commission (EC)...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-9803 and SHR-A2102 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Servier and Black Diamond Therapeutics Ink Global Deal for Solid Tumor Targeted Therapy BDTX-4933
French pharmaceutical firm Servier has announced a global licensing agreement with US-based Black Diamond Therapeutics...
Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s...
Shanghai Junshi Biosciences’ Loqtorzi Approved in Singapore for Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval from...
Zhejiang Funow Medicine Launches Triple Cream for Melasma Treatment in China
China-based Zhejiang Fonow Medicine Co., Ltd. (formerly known as: Zhejiang Rishengchang Pharmaceutical Co., Ltd.) has...
Luye Pharma’s BA1302 Receives FDA Orphan Drug Designation for Lung and Pancreatic Cancer
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...
Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&D with AI
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into a collaboration with compatriot...
Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372
German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe...
AstraZeneca’s Calquence Approved by NMPA for CLL/SLL Treatment
UK pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving another indication approval from China’s National...
Shanghai ZJ Bio-Tech’s HCV Nucleic Acid Test Kit Receives NMPA Approval
China-based molecular diagnostic reagent specialist Shanghai Liferiver Bio-Tech Co., Ltd (SHA: 688317) has announced receiving...
Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources
China’s Shanghai RAAS (SHE: 002252) has announced plans to acquire 100% stakes in compatriot firm...
Sichuan Huiyu Pharmaceutical Wins Marketing Approvals in Italy, Portugal, Saudi Arabia
China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) has announced its its subsidiaries Seacross Pharma...
Merck KGaA Partners with Roche to Commercialize Tepmetko in China
Germany-based pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a partnership with Swiss giant...
China Resources Medical Holdings Reports 2024 Revenue of RMB9.86 Billion Amid Net Profit Surge
China Resources Medical Holdings Company Ltd (CR Medical, HKG: 1515) has published its 2024 financial...